FRONT-2 enrolled treatment-naïve and recently diagnosed treatment-experienced wet AMD patients, unlike the ...
Verastem, Inc. kept at Buy on KRAS G12D catalysts and strong PDAC data; read TARGET-D 101 & VS-7375 updates plus cash runway ...
Ocular said its U.S. Food and Drug Administration-aligned New Drug Application for wet age-related macular degeneration ...
Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A ...
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial Intismeran autogene (intismeran; formerly ...
Novo Nordisk advances post‑Wegovy strategy with stronger obesity, diabetes data Novo Nordisk touts real‑world and late‑stage results for CagriSema and Zenagamtide at ADA 2026 ...
After a four-month investigation, Nature Medicine has decided to pull a viral study that linked early-day PD-1/chemo ...
Results from prespecified assessment of End of Progression™ in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in an oral presentationEvidence on the ...
India vs Afghanistan 3rd ODI Highlights: India completed a clean sweep of the three-match ODI series with a comprehensive ...
Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH ...
Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial
Abivax plans to file for FDA approval toward the end of the year. (Getty Images/Lemon_tm) Abivax has raised the efficacy bar in ulcerative colitis, linking obefazimod to a 40%, placebo-adjusted jump ...
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results